LY354740: A systemically active mGlu2/mGlu3 receptor agonist

Darryle D. Schoepp, James A. Monn, Gerard J. Marek, George Aghajanian, Bita Moghaddam

Research output: Contribution to journalReview article

23 Citations (Scopus)

Abstract

In summary, in vitro and in vivo studies have shown LY354740 to be a highly novel pharmacological agent with multiple possible therapeutic applications: 1. LY354740 is a nM potent agonist for group II mGlu receptors and has no appreciable activities at ionotropic glutamate receptors or other subtypes of mGlu receptors at concentrations which activate group II mGlu2 and mGlu3 receptors. 2. Modulation of synaptic transmission by LY354740 appears to involve presynaptic and possibly postsynaptic mechanisms. LY354740 acts at select synapses where mGlu2/mGlu3 receptors are expressed to suppress excitatory transmission when evoked by various means that include excitatory 5HT(2A) receptors and depolarization-induced release of glutamate. 3. LY354740 has shown activity in certain benzodiazepine-sensitive models of fear/anxiety in animals without the secondary pharmacology (i.e., sedation, motor impairment) observed with other anxiolytics. 4. LY354740 has been reported to suppress withdrawal phenomena associated with diazepam, nicotine, and morphine in rats. 5. LY354740 has been reported to selectively suppress release of glutamate and behavioral disruptions subsequent to PCP administration in rats. 6. LY354740 has been shown to protect excitotoxic injury to neurons in vitro and provide some protection against traumatic and ischemic injury to neurons. Additional studies, however, are warranted to clarify the neuroprotectant properties of this mechanism for acute stroke. The above-described disorders of the CNS have in common excessive or pathologically enhanced glutamate transmission in specific synapses and neuronal circuits of the brain. Thus, activation of mGlu2/mGlu3 receptors by LY354740 represents a highly novel mechanism for suppression of pathologically enhanced glutamate transmission, and the possible treatment of certain psychiatric and neurological conditions (Fig. 3).

Original languageEnglish (US)
Pages (from-to)1-12
Number of pages12
JournalCNS Drug Reviews
Volume5
Issue number1
StatePublished - 1999
Externally publishedYes

Fingerprint

eglumetad
Glutamic Acid
Synapses
Pharmacology
Ionotropic Glutamate Receptors
Neurons
Anti-Anxiety Agents
Wounds and Injuries
Neuroprotective Agents
Diazepam
Benzodiazepines
Nicotine
Synaptic Transmission
Morphine
Fear
Psychiatry
Anxiety

Keywords

  • Anxiety
  • Drug withdrawal
  • LY354740
  • Metabotropic glutamate receptors
  • mGlu receptors
  • mGlu2 receptor
  • mGlu3 receptor
  • Psychosis

ASJC Scopus subject areas

  • Pharmacology
  • Neuropsychology and Physiological Psychology

Cite this

Schoepp, D. D., Monn, J. A., Marek, G. J., Aghajanian, G., & Moghaddam, B. (1999). LY354740: A systemically active mGlu2/mGlu3 receptor agonist. CNS Drug Reviews, 5(1), 1-12.

LY354740 : A systemically active mGlu2/mGlu3 receptor agonist. / Schoepp, Darryle D.; Monn, James A.; Marek, Gerard J.; Aghajanian, George; Moghaddam, Bita.

In: CNS Drug Reviews, Vol. 5, No. 1, 1999, p. 1-12.

Research output: Contribution to journalReview article

Schoepp, DD, Monn, JA, Marek, GJ, Aghajanian, G & Moghaddam, B 1999, 'LY354740: A systemically active mGlu2/mGlu3 receptor agonist', CNS Drug Reviews, vol. 5, no. 1, pp. 1-12.
Schoepp DD, Monn JA, Marek GJ, Aghajanian G, Moghaddam B. LY354740: A systemically active mGlu2/mGlu3 receptor agonist. CNS Drug Reviews. 1999;5(1):1-12.
Schoepp, Darryle D. ; Monn, James A. ; Marek, Gerard J. ; Aghajanian, George ; Moghaddam, Bita. / LY354740 : A systemically active mGlu2/mGlu3 receptor agonist. In: CNS Drug Reviews. 1999 ; Vol. 5, No. 1. pp. 1-12.
@article{1815fe5f98364761aec5f3bbc2228318,
title = "LY354740: A systemically active mGlu2/mGlu3 receptor agonist",
abstract = "In summary, in vitro and in vivo studies have shown LY354740 to be a highly novel pharmacological agent with multiple possible therapeutic applications: 1. LY354740 is a nM potent agonist for group II mGlu receptors and has no appreciable activities at ionotropic glutamate receptors or other subtypes of mGlu receptors at concentrations which activate group II mGlu2 and mGlu3 receptors. 2. Modulation of synaptic transmission by LY354740 appears to involve presynaptic and possibly postsynaptic mechanisms. LY354740 acts at select synapses where mGlu2/mGlu3 receptors are expressed to suppress excitatory transmission when evoked by various means that include excitatory 5HT(2A) receptors and depolarization-induced release of glutamate. 3. LY354740 has shown activity in certain benzodiazepine-sensitive models of fear/anxiety in animals without the secondary pharmacology (i.e., sedation, motor impairment) observed with other anxiolytics. 4. LY354740 has been reported to suppress withdrawal phenomena associated with diazepam, nicotine, and morphine in rats. 5. LY354740 has been reported to selectively suppress release of glutamate and behavioral disruptions subsequent to PCP administration in rats. 6. LY354740 has been shown to protect excitotoxic injury to neurons in vitro and provide some protection against traumatic and ischemic injury to neurons. Additional studies, however, are warranted to clarify the neuroprotectant properties of this mechanism for acute stroke. The above-described disorders of the CNS have in common excessive or pathologically enhanced glutamate transmission in specific synapses and neuronal circuits of the brain. Thus, activation of mGlu2/mGlu3 receptors by LY354740 represents a highly novel mechanism for suppression of pathologically enhanced glutamate transmission, and the possible treatment of certain psychiatric and neurological conditions (Fig. 3).",
keywords = "Anxiety, Drug withdrawal, LY354740, Metabotropic glutamate receptors, mGlu receptors, mGlu2 receptor, mGlu3 receptor, Psychosis",
author = "Schoepp, {Darryle D.} and Monn, {James A.} and Marek, {Gerard J.} and George Aghajanian and Bita Moghaddam",
year = "1999",
language = "English (US)",
volume = "5",
pages = "1--12",
journal = "CNS Drug Reviews",
issn = "1080-563X",
publisher = "Neva Press, Inc.",
number = "1",

}

TY - JOUR

T1 - LY354740

T2 - A systemically active mGlu2/mGlu3 receptor agonist

AU - Schoepp, Darryle D.

AU - Monn, James A.

AU - Marek, Gerard J.

AU - Aghajanian, George

AU - Moghaddam, Bita

PY - 1999

Y1 - 1999

N2 - In summary, in vitro and in vivo studies have shown LY354740 to be a highly novel pharmacological agent with multiple possible therapeutic applications: 1. LY354740 is a nM potent agonist for group II mGlu receptors and has no appreciable activities at ionotropic glutamate receptors or other subtypes of mGlu receptors at concentrations which activate group II mGlu2 and mGlu3 receptors. 2. Modulation of synaptic transmission by LY354740 appears to involve presynaptic and possibly postsynaptic mechanisms. LY354740 acts at select synapses where mGlu2/mGlu3 receptors are expressed to suppress excitatory transmission when evoked by various means that include excitatory 5HT(2A) receptors and depolarization-induced release of glutamate. 3. LY354740 has shown activity in certain benzodiazepine-sensitive models of fear/anxiety in animals without the secondary pharmacology (i.e., sedation, motor impairment) observed with other anxiolytics. 4. LY354740 has been reported to suppress withdrawal phenomena associated with diazepam, nicotine, and morphine in rats. 5. LY354740 has been reported to selectively suppress release of glutamate and behavioral disruptions subsequent to PCP administration in rats. 6. LY354740 has been shown to protect excitotoxic injury to neurons in vitro and provide some protection against traumatic and ischemic injury to neurons. Additional studies, however, are warranted to clarify the neuroprotectant properties of this mechanism for acute stroke. The above-described disorders of the CNS have in common excessive or pathologically enhanced glutamate transmission in specific synapses and neuronal circuits of the brain. Thus, activation of mGlu2/mGlu3 receptors by LY354740 represents a highly novel mechanism for suppression of pathologically enhanced glutamate transmission, and the possible treatment of certain psychiatric and neurological conditions (Fig. 3).

AB - In summary, in vitro and in vivo studies have shown LY354740 to be a highly novel pharmacological agent with multiple possible therapeutic applications: 1. LY354740 is a nM potent agonist for group II mGlu receptors and has no appreciable activities at ionotropic glutamate receptors or other subtypes of mGlu receptors at concentrations which activate group II mGlu2 and mGlu3 receptors. 2. Modulation of synaptic transmission by LY354740 appears to involve presynaptic and possibly postsynaptic mechanisms. LY354740 acts at select synapses where mGlu2/mGlu3 receptors are expressed to suppress excitatory transmission when evoked by various means that include excitatory 5HT(2A) receptors and depolarization-induced release of glutamate. 3. LY354740 has shown activity in certain benzodiazepine-sensitive models of fear/anxiety in animals without the secondary pharmacology (i.e., sedation, motor impairment) observed with other anxiolytics. 4. LY354740 has been reported to suppress withdrawal phenomena associated with diazepam, nicotine, and morphine in rats. 5. LY354740 has been reported to selectively suppress release of glutamate and behavioral disruptions subsequent to PCP administration in rats. 6. LY354740 has been shown to protect excitotoxic injury to neurons in vitro and provide some protection against traumatic and ischemic injury to neurons. Additional studies, however, are warranted to clarify the neuroprotectant properties of this mechanism for acute stroke. The above-described disorders of the CNS have in common excessive or pathologically enhanced glutamate transmission in specific synapses and neuronal circuits of the brain. Thus, activation of mGlu2/mGlu3 receptors by LY354740 represents a highly novel mechanism for suppression of pathologically enhanced glutamate transmission, and the possible treatment of certain psychiatric and neurological conditions (Fig. 3).

KW - Anxiety

KW - Drug withdrawal

KW - LY354740

KW - Metabotropic glutamate receptors

KW - mGlu receptors

KW - mGlu2 receptor

KW - mGlu3 receptor

KW - Psychosis

UR - http://www.scopus.com/inward/record.url?scp=0032886131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032886131&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:0032886131

VL - 5

SP - 1

EP - 12

JO - CNS Drug Reviews

JF - CNS Drug Reviews

SN - 1080-563X

IS - 1

ER -